Yusimry Approved as Humira Biosimilar
September 20, 2021Opzelura Cream Approved to Treat Atopic Dermatitis
September 21, 2021September 20, 2021 – TivdakTM (tisotumab vedotin-tftv) is now U.S. FDA approved to treat recurrent or metastatic cervical cancer in patients whose disease has progressed on or after chemotherapy.
- Manufactured by Genmab and Seagen, it is the first antibody-drug conjugate to be FDA approved for this indication.
- Recommended dosing is 2mg/kg of the patient’s body weight, up to a maximum of 200mg, given via 30-minute intravenous infusion every three weeks until disease progression or unacceptable toxicity occur.
- Tivdak has a wholesale acquisition cost (WAC) of $5,885 per 40mg single-dose vial.